EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Zhoujunyi Tian, Haoshuai Yang, Jin Zhang, Qiduo Yu, Deruo Liu, Meng Yang, Zhenrong Zhang, Chaoyang Liang

Frontiers in Oncology · 28.05.2026 · 16

DOI: 10.3389/fonc.2026.1837880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.05.2026. Verfasst von Zhoujunyi Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant chemoimmunotherapy and adjuvant immunotherapy is a standard of care for resectable non-small cell lung cancer. However, high non-adherence rates challenge its implementation and benefits. We assessed the risks and long-term outcomes of completing this full regimen versus non-completion in a real-world setting.

Methods

Patients with resectable non-small cell lung cancer at clinical stage IB-IIIB who received neoadjuvant chemoimmunotherapy followed by surgery were included. Patients were divided into a completed group (n=37), who received four cycles of perioperative chemoimmunotherapy and one year of adjuvant immunotherapy, and a non-completed group (n=127). Inverse Probability of Treatment Weighting was used to adjust baseline characteristics. Kaplan-Meier curves compared recurrence-free survival, overall survival, and cumulative hazard of adverse events. Cox regression models assessed predictors for recurrence and subgroup analyses were performed.

Results

No significant differences were in recurrence-free survival (P = 0.85) or overall survival (P = 0.34) between the two groups. Positive pathological nodal status was an independent predictor of recurrence, while completion status was not (adjusted hazard ratio 1.14, 95% CI 0.24-5.50, P = 0.87). The completed group experienced a higher incidence of any-grade adverse events (AEs), but no significant increase in Grade 3/4 AEs. Subgroup analysis revealed a notable recurrence benefit from completion in patients who were aged <65 years and ECOG score 0.

Conclusion

Completing perioperative chemoimmunotherapy protocol did not significantly increase the risk of severe AEs, but also failed to demonstrate a survival benefit. Prospective studies and extended follow-up duration were needed to verify the conclusions.

Schlagwörter

Stichwörter der Autor:innen

chemoimmunotherapynon-adherencenon–small cell lung cancerperioperativerecurrence-free survival

Autor:innen und Institutionen

  • Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.

Zitieren

APA

Tian, Z., Yang, H., Zhang, J., Yu, Q., Liu, D., Yang, M., Zhang, Z., & Liang, C. (2026). Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1837880

Vancouver

Tian Z, Yang H, Zhang J, Yu Q, Liu D, Yang M, et al. Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1837880

BibTeX
@article{Tian2026,
  author = {Tian, Zhoujunyi and Yang, Haoshuai and Zhang, Jin and Yu, Qiduo and Liu, Deruo and Yang, Meng and Zhang, Zhenrong and Liang, Chaoyang},
  title = {Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1837880}
}
Kostenlos starten →